Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Non-cash Items (2022 - 2025)

Historic Non-cash Items for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $683000.0.

  • BioXcel Therapeutics' Non-cash Items fell 8246.47% to $683000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $683000.0, marking a year-over-year decrease of 8246.47%. This contributed to the annual value of $7.7 million for FY2024, which is 1885.42% down from last year.
  • According to the latest figures from Q3 2025, BioXcel Therapeutics' Non-cash Items is $683000.0, which was down 8246.47% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, BioXcel Therapeutics' Non-cash Items ranged from a high of $22.8 million in Q1 2022 and a low of $259000.0 during Q1 2025
  • Over the past 4 years, BioXcel Therapeutics' median Non-cash Items value was $3.9 million (recorded in 2024), while the average stood at $7.9 million.
  • Per our database at Business Quant, BioXcel Therapeutics' Non-cash Items soared by 3574.98% in 2024 and then tumbled by 9292.74% in 2025.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' Non-cash Items stood at $15.5 million in 2022, then crashed by 38.78% to $9.5 million in 2023, then fell by 18.85% to $7.7 million in 2024, then crashed by 91.12% to $683000.0 in 2025.
  • Its Non-cash Items was $683000.0 in Q3 2025, compared to $1.1 million in Q2 2025 and $259000.0 in Q1 2025.